Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Июнь 1, 2024

Язык: Английский

---

Disparities in steatosis prevalence in the United States by Race or Ethnicity according to the 2023 criteria

Communications Medicine, Год журнала: 2024, Номер 4(1)

Опубликована: Окт. 29, 2024

The 2023 nomenclature defined criteria for steatotic liver disease (SLD), including metabolic dysfunction-associated SLD (MASLD), alcohol-associated (ALD), and the overlapping MASLD/ALD (MetALD). We aimed to assess racial ethnic disparities in prevalence among United States (US) adults based on this new nomenclature. undertook a cross-sectional study employing 2017–2018 National Health Nutrition Examination Survey (NHANES) database. identified according controlled attenuation parameter ≥288 dB/m, stiffness ≥7.2 kPa, or elevated aminotransferase levels. Alcohol use thresholds were established updated definition. estimated prevalences using complex design of NHANES survey. Multivariable logistic regressions with weights employed. A total 5532 individuals are included. mean age is 45.4 years, 50.9% women. adjusted MASLD 42.4% (95% CI: 41.1–43.8%), MetALD 1.7% 1.3–2.0%), ALD 0.6% 0.3–0.8%). Hispanics exhibit higher SLD, but there no significant differences advanced fibrosis due racial/ethnic groups. In MASLD, men, aged 40–64 ≥65 Hispanics, those health insurance, BMI, diabetes, hypertension, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol lipid-lowering agents independently associated risk, while Blacks have lowest risk. MetALD, men BMI risk multivariable analysis. ALD, analysis shows that only insurance lower high US, especially older individuals, Hispanics. was substantial could be underestimated. This aims estimate different types fatty disease, which excess fat occurs liver. particular type not caused by alcohol consumption affects USA, adults, being more likely form disease. People less consumption. These results highlight importance targeted prevention efforts people developing Future public strategies should focus reducing factors providing equitable healthcare access. Díaz et al. (SLD) States. Increased waist circumference, weight, abnormal glucose metabolism, hypertension sex, hispanic ethnicity lack certain types.

Язык: Английский

---

Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among US Adults, 2017–2023

Alimentary Pharmacology & Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Янв. 11, 2025

Our study investigated the prevalence of lean steatotic liver disease (SLD) and its subcategories, including metabolic dysfunction-associated (MASLD), dysfunction-related alcohol-related SLD (MetALD), (ALD) among adults in US. Analysing data from 2965 (≥ 18 years) National Health Nutrition Examination Survey (2017-2023), we found age-adjusted to be 12.8%. Specifically, was 9.3% for MASLD, 1.3% MetALD 1.0% ALD. Notably, within MASLD group, significant fibrosis, advanced cirrhosis were observed 5.6%, 2.4% 2.0%, respectively.

Язык: Английский

---

Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD

˜The œLancet. Gastroenterology & hepatology, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

---

All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Дек. 1, 2024

Язык: Английский

---

Machine learning across multiple imaging and biomarker modalities in the UK Biobank improves genetic discovery for liver fat accumulation

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Янв. 7, 2024

Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD), with more than 5.5% fat content, is a leading risk factor for chronic an estimated worldwide prevalence of 30%. Though MASLD widely recognized to be polygenic, genetic discovery has been lacking primarily due the need accurate and scalable phenotyping, which proves costly, time-intensive variable in quality. Here, we used machine learning (ML) predict content using three different data modalities available UK Biobank: dual-energy X-ray absorptiometry (DXA; n = 46,461 participants), plasma metabolites (n 82,138), anthropometric blood-based biochemical measures (biomarkers; 262,927). Based on our estimates, up 29% participants UKB met criteria MASLD. Genome-wide association studies (GWASs) these estimates identified 15, 55, 314 loci associated predicted from DXA, biomarkers, respectively, totalling 321 unique independent loci. In addition replicating 9 14 known at genome-wide significance, GWASs 312 novel loci, significantly expanding understanding contributions accumulation. Genetic correlation analysis indicated strong between ML-derived across ( r g ranging 0.85 0.96) clinically diagnosed 0.74 0.88), suggesting that majority newly are likely relevant clinical DXA exhibited highest precision, while biomarkers demonstrated recall, respectively. Overall, findings demonstrate value leveraging ML-based trait predictions orthogonal sources improve architecture complex diseases.

Язык: Английский

---

A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease

Journal of Hepatology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Язык: Английский

---

Metabolic Dysfunction-Associated Steatotic Liver Disease and Polycystic Ovary Syndrome: A Complex Interplay

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(14), С. 4243 - 4243

Опубликована: Июль 20, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) and polycystic ovary syndrome (PCOS) are prevalent conditions that have been correlated with infertility through overlapped pathophysiological mechanisms. MASLD is associated metabolic considered among the major causes of chronic disease, while PCOS, which characterized by ovulatory dysfunction hyperandrogenism, one leading female infertility. The links between PCOS not yet fully elucidated, insulin resistance, hyperandrogenemia, obesity, dyslipidemia being key pathways contribute to lipid accumulation, inflammation, fibrosis, aggravating dysfunction. On other hand, exacerbates resistance dysregulation in women creating a vicious cycle progression. Understanding intricate relationship crucial improving clinical management, collaborative efforts different medical specialties essential optimize fertility health outcomes individuals PCOS. In this review, we summarize complex interplay highlighting importance increasing attention prevention, diagnosis, treatment both entities.

Язык: Английский

---

Lingguizhugan oral solution alleviates MASLD by regulating bile acids metabolism and the gut microbiota through activating FXR/TGR5 signaling pathways

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Авг. 15, 2024

Background The preservation of the Lingguizhugan (LGZG) decoction and patient compliance issue often limit treatment metabolic dysfunction-associated steatotic liver disease (MASLD). Hence, herein, an LGZG oral solution was developed for alleviating MASLD. Additionally, potential mechanisms underlying LGZG-mediated MASLD mitigation were explored. Methods A mouse model constructed using oleic palmitic acid-induced LO2 cells a high-fat diet. apoptosis, lipid deposition, function analyzed to assess therapeutic effects on Serum untargeted metabolomics, gut microbiota, bile acid (BA) metabolism, immunohistochemistry, Western blotting analyses performed investigate mechanism action Results ameliorated oxidative stress, inflammation, pathological damage. metabolomics results revealed regulation primary BA biosynthetic pathway. 16S ribosomal RNA sequencing fecal microbiota showed that increased relative abundance metabolism-associated Bacteroides , Akkermansia decreased Lactobacillus . metabolism analysis decrease in total taurine-α/β-muricholic levels, whereas those deoxycholic increased, which activated specific receptors ileum, including farnesoid X receptor (FXR) takeda G protein-coupled 5 (TGR5). Activation FXR resulted increase short heterodimer partner subsequent inhibition cholesterol 7α-hydroxylase sterol regulatory element-binding protein-1c expression, activation also upregulation fibroblast growth factor 15/19 consequently 7α-hydroxylase, correlated with hepatic synthesis lipogenesis, ultimately attenuating deposition stasis, thereby improving Conclusion Altogether, findings this study suggest modulating microbiota–BA–FXR/TGR5 signaling pathway may be

Язык: Английский

---

Diet quality and physical activity affect metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction and etiology-associated steatohepatitis, and compensated advanced chronic liver disease among United States adults: NHANES 2017–2020

Frontiers in Nutrition, Год журнала: 2025, Номер 11

Опубликована: Янв. 8, 2025

Clinical data on the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and dysfunction etiology-associated steatohepatitis (MetALD) in a multi-ethnic U.S. population are limited. Additionally, impact physical activity (PA) diet quality (DQ) risk MASLD, MetALD, compensated advanced chronic (cACLD) remains unclear. This study aimed to investigate associations PA with risks cACLD. cross-sectional analyzed from 7,125 participants National Health Nutrition Examination Survey (NHANES) 2017-2020. Diet was assessed using Healthy Eating Index-2015 (HEI-2015). based 2020 WHO Physical Activity Guidelines, reporting intensity, frequency, duration their activities over past 7 days. MASLD MetALD were diagnosed clinical criteria, cACLD defined by fibrosis. Bivariate multivariable logistic regression models used assess between PA, quality, outcomes. The 35.07 21.46%, respectively. HQD associated significantly lower (OR: 0.49, 95% CI: 0.38-0.62) 0.45, 0.36-0.56). High levels linked reduced 0.47, 0.38-0.58) 0.53, 0.39-0.72). lowest for both observed highly active an (MASLD OR: 0.41, 0.32-0.53; 0.54, 0.41-0.71). Significant interactions HQD, age, BMI, SES, which further MetALD. For cACLD, increased risk. Compared non-high-activity non-HQD, physically had 0.44, 0.24-0.82). proportions US have or high

Язык: Английский

---